Related Experiment Video
Updated: Apr 30, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
17.7K
Epratuzumab for systemic lupus erythematosus.
1University of Medicine and Pharmacy, Department of Interdisciplinarity - Palliative Care Nursing , 16 Universităţii Str, Iasi, 700115, Grigore T Popa Iasi , Romania sabina.antonela.antoniu@pneum.umfiasi.ro.
Expert Opinion on Biological Therapy
|April 30, 2014
Summary
Epratuzumab, an anti-CD22 antibody, shows potential in treating systemic lupus erythematosus by improving quality of life and reducing disease activity. Further data is needed due to early study terminations.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a severe autoimmune disease with significant morbidity and mortality.
- Current immunosuppressive therapies (e.g., corticosteroids, cyclophosphamide) have limitations.
- Novel therapeutic strategies are crucial for managing SLE progression.
Purpose of the Study:
- To evaluate the efficacy and safety of epratuzumab in patients with moderate to severe SLE.
- To assess the impact of epratuzumab on disease activity and quality of life in SLE patients.
Main Methods:
- Review of clinical studies on epratuzumab in SLE patients.
- Analysis of efficacy and safety data from these trials.
Main Results:
- Epratuzumab demonstrated potential to improve patient quality of life.
- A reduction in disease activity burden was observed in treated patients.
- Premature study termination may have limited comprehensive efficacy assessment.
Conclusions:
- Epratuzumab offers a promising therapeutic option for SLE.
- Further research is warranted to fully establish its long-term efficacy and safety profile.
- Targeting CD22 with epratuzumab may be a viable strategy in SLE management.
